Co-led Slate Medicines' $130M Series A financing to advance anti-PACAP therapies for migraine prevention.
Slate Medicines is focused on advancing next-generation therapeutics for migraine and other headache disorders, addressing the significant disability and disease burden faced by patients
Slate Medicines is focused on advancing next-generation therapeutics for migraine and other headache disorders, addressing the significant disability and disease burden faced by patients.